Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Delayed Toronto S.E.
Other stock markets
 14:47:09 08/05/2024 BST 		5-day change 1st Jan Change
4.78 CAD +1.06% Intraday chart for HLS Therapeutics Inc. +2.80% +21.01%
04-08 HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA CI
03-14 Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA
CI
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update
MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022
MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million
MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024
CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan
MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan
MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo
MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
MT
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses
CI
HLS Therapeutics Inc.'s Equity Buyback announced on November 10, 2022, has expired.
CI
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.
CI
HLS Therapeutics Inc. announces an Equity Buyback for 1,607,892 shares, representing 5% of its issued share capital.
CI
HLS Therapeutics Reports Q3 2023 Revenue of US$16.0 Million, Renews Normal Course Issuer Bid
MT
HLS Therapeutics Brief: Q3 2023 revenue was US$16.0 million, Adjusted EBITDA was $5.1 million and cash from operations was $5.4 million; Renewing Normal Course Issuer Bid
MT
HLS Therapeutics Inc. authorizes a Buyback Plan.
CI
HLS Therapeutics Q2 Net Loss; Revenue was US$16.4 Million, Vascepa Net Revenue up 49% YoY
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLS Stock
  4. News HLS Therapeutics Inc.
  5. Highlights